CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis - Université de Tours Accéder directement au contenu
Article Dans Une Revue British Journal of Clinical Pharmacology Année : 2019

CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis

Résumé

Rituximab is approved in rheumatoid arthritis (RA). A substantial decrease in CD4+ count was observed in responders after a single cycle of treatment. This study aimed at describing and quantifying the influence of CD4+ count depletion on the concentration-response relationship of rituximab in RA patients.

Dates et versions

hal-02376303 , version 1 (22-11-2019)

Identifiants

Citer

Amina Bensalem, Denis Mulleman, Gilles Thibault, Nicolas Azzopardi, Philippe Goupille, et al.. CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis. British Journal of Clinical Pharmacology, 2019, ⟨10.1111/bcp.14102⟩. ⟨hal-02376303⟩

Collections

UNIV-TOURS CNRS
62 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More